EU Agency Recommends GlaxoSmithKline Kidney Cancer Drug

February 19, 2010 |

1 min read

Reuters -- European regulators recommended GlaxoSmithKline's new kidney cancer drug Votrient for conditional approval on Friday, paving the way for its rollout across the European Union.

Regulatory

GlaxoSmithKline

MORE ON THIS TOPIC

Podcast

FDA Layoffs, 200 Rejection Letters, User Fees and Priority Vouchers, Bad Week for Rare Disease

July 16, 2025

·

1 min read

·

Heather McKenzie

Entrance to the U.S. Department of Health and Human Services in Washington, DC

Layoffs

HHS Begins Formally Laying Off Employees

July 15, 2025

·

2 min read

·

Tristan Manalac

Policy

FDA Commissioner Marty Makary Proposes Lowering Industry User Fees

July 15, 2025

·

2 min read

·

Tristan Manalac

World Management Team in office silhouette 3d rendering

Drug Development

The Gap Between the Administration’s Pro-Innovation Words and Policy

July 14, 2025

·

6 min read

·